Trial Profile

Phase I, Open Label, Dose Escalating Study to Investigate Safety and Tolerability of Intravesical Application of Trifunctional Anti-EPCAM x Anti-CD3 Antibody Catumaxomab in Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catumaxomab (Primary)
Indications Bladder cancer; Carcinoma; Prostate cancer; Urethral cancer; Urogenital cancer
Focus Adverse reactions
Sponsors Lindis Biotech

07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
04 Apr 2022 Planned primary completion date changed from 30 Dec 2021 to 30 Dec 2022.
01 Apr 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com